share_log

Citizens Capital Markets Reiterates Market Outperform on AN2 Therapeutics, Maintains $5 Price Target

Benzinga ·  Mar 26 13:07

Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 400

Recommended

Write a comment